Can we predict myelotoxicity development during thiopurine therapy for inflammatory bowel disease?

Аннотация

Myelotoxicity occurs in 2 25% patients as side effect during treatment with azathioprine (AZA) and 6-mercaptopurine (6MP). Aim of study was to determinate frequency of the G238C, A719G, and G460A TPMT gene polymorphisms and to measure the TPMT enzyme activity in red blood cells in Russian inflammatory bowel disease (IBD) patients with myelotoxicity during AZA/6MP treatment.